by Raynovich Rod | Jun 24, 2019 | Biopharmaceuticals, Macro
Update-2… 6/27 2p EDT…Good day for gene therapy stocks My longs CRSP and MGTX are up. Looking better all across the screen in biopharma. Added to ABBV and XNCR yesterday. XBI up but still under $86. Update-1… Another Big Deal in Biotech in a weak...
by Raynovich Rod | Jun 10, 2019 | Biopharmaceuticals, Macro
Update-3 6/17 11:30 a EDT Pfizer (PFE) $11B Buyout of Array Pharmaceuticals (ARRY) Sparks Rally in biotech. As usual M&A brings buyers into biotech. ARRY up 56% on Pfizer $11B buyout. XBI up 3.68% to $84.46. Green screen in mid-caps, gene therapy. ==========...
by Raynovich Rod | Jun 5, 2019 | Biopharmaceuticals, Macro
Update-3…6/7- 1p EDT… Broad Tech Rally Underway Hot stocks in life science: CRSP, GILD, GSK, ILMN, VRTX, XBI up 1.56%. Update-2 …Bit of a rally at the close on the day-to-day tariff drama- now softening on Mexican tariffs; way too much obsession and...
by Raynovich Rod | May 28, 2019 | Biopharmaceuticals, Macro
Update-2 5/31 2:15 p EDT. Impossible to invest with current Tariff Headwinds-XBI down 1.24% to $79.83. NASDAQ down 1.33%. ========= Update-1 5/29… Better Tape Today Off Lows Despite 1.1% Drop in IBB and 0.93% in XBI One of our top picks from JPM was Amarin...
by Raynovich Rod | May 21, 2019 | Biopharmaceuticals, Macro
Update-2…3:15p EDT…. Mixed day-new post after close, XBI down 0.64%, IBB down 0.94%,, Dow sell-off down 0.43%. ====== Update-1 5/22… Not much follow-through from yesterday but trade-able.A horrible news week with politics, tariffs, chips and China...
by Raynovich Rod | Jan 17, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-2 1/21/19…Heads Up Red Futures Growth worries return-Asian Stocks down IMF Lowers Global Growth-Poor Performance for Europe Biotech rally could stall Update-1 1/20/19…XBI at $83.38 approaching November resistance at $85 Barron’s 2019...
by Raynovich Rod | Dec 13, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-2 After close: Market Collapses After FED Meeting-Bear Market WE all knew that the biotech sector likes looser monetary policy but this sell-off is ridiculous. The IBB is now at May 2017 levels! XBI breaks through 2018 technicals down 3.33% on downside to...
by Raynovich Rod | Dec 5, 2018 | Biopharmaceuticals, Macro
Update -4 After Close 12/7/18 Market Performance for the Week XBI down 7.8%, IBB down 6.6%, XLV down 5.2%, QQQ down 5.11%. Futures not looking good at 12:40a EST, NAZ down 0.82%. Global Growth worries mount; geopolitical turmoil reigns. Moderna (MRNA) IPO closes down...
by Raynovich Rod | Oct 10, 2018 | Biopharmaceuticals, Macro
Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum...
by Raynovich Rod | Oct 4, 2018 | Biopharmaceuticals, Macro
Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers...
